7月30日，百特国际盘前上涨9%，报27.1美元/股，成交额153.44万美元。
消息面上，公司发布第二季度财报，调整后每股收益0.54美元，大幅超越市场一致预期的0.37美元，超出幅度达45.95%；营收29.6亿美元，高于预期的27.95亿美元。尽管同比来看，调整后每股收益较去年同期的0.59美元下降8.47%，但远超市场预期的表现提振了投资者信心。
值得注意的是，此前多家投行已集中上调百特目标价：Stifel于7月28日将目标价从19美元上调至24美元，Evercore ISI上调至24美元，高盛上调至21美元。当前分析师平均目标价为21美元。结合Q1同样超预期的业绩表现，公司经营改善趋势正获得市场进一步认可。
百特国际有限公司提供广泛的基本医疗保健产品，包括无菌静脉溶液、输液系统和设备、肠外营养疗法、吸入麻醉剂、仿制注射剂、手术止血剂和密封剂产品及智能床系统等。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.